AdvisorShares MSOS Daily Leveraged ETF (MSOX)

Wall Street was moderately upbeat last week.

Cannabis ETFs are experiencing one of their most dynamic years yet, driven by significant regulatory shifts. The Department of Health and Human Services‘ recommendation to reclassify cannabis from a Schedule I to a Schedule III drug under the Controlled Substances Act marks a pivotal moment. This change, coupled with growing Congressional support led by figures like Elizabeth Warren and Chuck Schumer, has invigorated the market. Investment Trends Amidst Regulatory Shifts As cannabis transitions from a Schedule I drug, investors are keenly observing the ETFs that are positioned to benefit. According to Jane Edmonds’ article on ETF Trends, the introduction of swap options for U.S. Multi-State Operators (MSOs) has created a unique ...Full story available on Benzinga.com

These cannabis stocks and ETFs stand to benefit if the proposed rescheduling of the substance takes place.